IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i22p15359-d978861.html
   My bibliography  Save this article

Clinical Use of Lansoprazole and the Risk of Osteoporosis: A Nationwide Cohort Study

Author

Listed:
  • Ming-Hsuan Chung

    (Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan)

  • Yong-Chen Chen

    (Data Science Center, College of Medicine, Fu-Jen Catholic University, New Taipei City 242, Taiwan
    Department of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei City 242, Taiwan)

  • Wen-Tung Wu

    (Department of Pharmacy, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
    School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan)

  • Ming-Hsun Lin

    (Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan)

  • Yun-Ju Yang

    (Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan)

  • Dueng-Yuan Hueng

    (Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan)

  • Tsung-Kun Lin

    (School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan)

  • Yu-Ching Chou

    (School of Public Health, National Defense Medical Center, Taipei 114, Taiwan)

  • Chien-An Sun

    (Data Science Center, College of Medicine, Fu-Jen Catholic University, New Taipei City 242, Taiwan
    Department of Public Health, College of Medicine, Fu-Jen Catholic University, New Taipei City 242, Taiwan)

Abstract

Background: Proton pump inhibitor (PPI) lansoprazole acts as a liver X receptor agonist, which plays a crucial role in the crosstalk of osteoblasts and osteoclasts in vitro and during bone turnover in vivo. However, epidemiological studies on the association between the use of lansoprazole and osteoporosis risk are limited. We aimed to determine the risk of developing osteoporosis in patients with lansoprazole use. Methods: A retrospective cohort study was conducted using the National Health Insurance Research Database of Taiwan dated from 2000 to 2013. The study includes 655 patients with lansoprazole use (the exposed cohort) and 2620 patients with other PPI use (the comparison cohort). The main outcome was the primary diagnosis of osteoporosis. The hazard ratios (HRs) and 95% confidence intervals (CIs) were used to assess the association between the use of lansoprazole and risk of osteoporosis. Results: Patients receiving lansoprazole treatment had a reduced risk of osteoporosis as compared with those undergoing other PPI therapy (adjusted HR, 0.56; 95% CI, 0.46–0.68). Moreover, this inverse association is evident in both sexes and in various age groups. Conclusions: This population-based cohort study demonstrated that lansoprazole use was associated with a reduced risk of osteoporosis. The clinical implications of the present study need further investigations.

Suggested Citation

  • Ming-Hsuan Chung & Yong-Chen Chen & Wen-Tung Wu & Ming-Hsun Lin & Yun-Ju Yang & Dueng-Yuan Hueng & Tsung-Kun Lin & Yu-Ching Chou & Chien-An Sun, 2022. "Clinical Use of Lansoprazole and the Risk of Osteoporosis: A Nationwide Cohort Study," IJERPH, MDPI, vol. 19(22), pages 1-9, November.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:22:p:15359-:d:978861
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/22/15359/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/22/15359/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Benjamin Ka Seng Thong & Soelaiman Ima-Nirwana & Kok-Yong Chin, 2019. "Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved," IJERPH, MDPI, vol. 16(9), pages 1-17, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:22:p:15359-:d:978861. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.